Aptamer–siRNA chimeras for HIV

Advances in Experimental Medicine and Biology

Volumn 848, Issue , 2015, Pages 211-234

  Takahashi, Mayumi ^a   Burnett, John C ^a   Rossi, John J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; CD4 ANTIBODY; CD4 ANTIGEN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; GP 120 ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS 1 PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; PEGAPTANIB; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS ANTIBODY; PEPTIDE APTAMER; RECOMBINANT DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CHIMERA; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; RNA SEQUENCE; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; ANIMAL; GENE THERAPY; GENETICS; HIV INFECTIONS; PROCEDURES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; ANTIGENS, CD4; APTAMERS, PEPTIDE; DNA, RECOMBINANT; GENETIC THERAPY; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; RNA, SMALL INTERFERING;

EID: 84924864415     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2432-5_11     Document Type: Article

References (154)

1. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305(24):1425-31.
2. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220(4599):868-71.
3. UNADS report on the global AIDS epidemic 2013, 2013.
4. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317(4):185-91.
5. Reust CE. Common adverse effects of antiretroviral therapy for HIV disease. Am Fam Physician. 2011;83(12):1443-51.
6. White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect. 2001;77(3):158-73.
7. Achhra AC, Boyd MA. Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature. AIDS Res Ther. 2013;10(1):33.
8. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)- infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37(5):613-27.
9. Group DADS, Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17): 1723-35.
10. Moore JP, Stevenson M. New targets for inhibitors of HIV-1 replication. Nat Rev Mol Cell Biol. 2000;1(1):40-9.
11. Stevenson M. HIV-1 pathogenesis. Nat Med. 2003;9(7):853-60.
12. Vaishnav YN, Wong-Staal F. The biochemistry of AIDS. Annu Rev Biochem. 1991;60: 577-630.
13. Sundquist WI, Krausslich HG. HIV-1 assembly, budding, and maturation. Cold Spring Harb Perspect Med. 2012;2(7):a006924.
14. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell. 1986;47(3):333-48.
15. McDougal JS, Kennedy MS, Sligh JM, Cort SP, Mawle A, Nicholson JK. Binding of HTLVIII/ LAV to T4+ T cells by a complex of the 110 K viral protein and the T4 molecule. Science. 1986;231(4736):382-5.
16. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996;272(5270):1955-8.
17. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996; 85(7):1135-48.
18. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381(6584):661-6.
19. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381(6584): 667-73.
20. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272(5263):872-7.
21. Wilen CB, Tilton JC, Doms RW. HIV: cell binding and entry. Cold Spring Harb Perspect Med. 2012;2(8):pii: a006866.
22. Corthesy B, Kao PN. Purification by DNA affinity chromatography of two polypeptides that contact the NF-AT DNA binding site in the interleukin 2 promoter. J Biol Chem. 1994; 269(32):20682-90.
23. Jones KA, Kadonaga JT, Luciw PA, Tjian R. Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1. Science. 1986;232(4751):755-9.
24. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature. 1987;326(6114):711-3.
25. Garber ME, Wei P, Jones KA. HIV-1 Tat interacts with cyclin T1 to direct the P-TEFb CTD kinase complex to TAR RNA. Cold Spring Harb Symp Quant Biol. 1998;63:371-80.
26. Arizala JR, Rossi JJ. Role of the nucleolus in HIV infection and therapy. In: Olson MOJ, editor. The nucleolus. Protein reviews. Springer: New York; 2011. p. 381-402.
27. Pollard VW, Malim MH. The HIV-1 Rev protein. Annu Rev Microbiol. 1998;52:491-532.
28. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents the US Department of Health and Human Services [updated February 12, 2013]. http://aidsinfo.nih.gov/contentfiles/lvguidelines/ adultandadolescentgl.pdf.
29. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669): 806-11.
30. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21- nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494-8.
31. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006;2(12):711-9.
32. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009;457(7228):426-33.
33. Dykxhoorn DM, Lieberman J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med. 2005;56:401-23.
34. Haasnoot J, Westerhout EM, Berkhout B. RNA interference against viruses: strike and counterstrike. Nat Biotechnol. 2007;25(12):1435-43.
35. Martinez MA. Progress in the therapeutic applications of siRNAs against HIV-1. Methods Mol Biol. 2009;487:343-68.
36. Subramanya S, Kim SS, Manjunath N, Shankar P. RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther. 2010;10(2):201-13.
37. Baker M. RNA interference: Homing in on delivery. Nature. 2010;464(7292):1225-8.
38. Blow N. Small RNAs: delivering the future. Nature. 2007;450(7172):1117-20.
39. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J. 2011;6(9):1130-46. Epub 2011/07/12.
40. Davidson BL, McCray Jr PB. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12(5):329-40.
41. Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev Genet. 2009;10(2):94-108.
42. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science. 2004;305(5689):1437-41.
43. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell. 2004;15(2):185-97.
44. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12(11):967-77.
45. Robbins M, Judge A, MacLachlan I. I siRNA and innate immunity. Oligonucleotides. 2009;19(2):89-102.
46. Cekaite L, Furset G, Hovig E, Sioud M. Gene expression analysis in blood cells in response to unmodified and 2'-modified siRNAs reveals TLR-dependent and independent effects. J Mol Biol. 2007;365(1):90-108.
47. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005;11(3):263-70.
48. Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther. 2006;13(3):494-505.
49. Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165-75.
50. Manoharan M, Akinc A, Pandey RK, Qin J, Hadwiger P, John M, et al. Unique gene- silencing and structural properties of 2′-fluoro-modified siRNAs. Angew Chem Int Ed Engl. 2011;50(10):2284-8.
51. Sioud M. Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2′-hydroxyl uridines in immune responses. Eur J Immunol. 2006;36(5):1222-30.
52. Friedrich BM, Dziuba N, Li G, Endsley MA, Murray JL, Ferguson MR. Host factors mediating HIV-1 replication. Virus Res. 2011;161(2):101-14.
53. Capodici J, Kariko K, Weissman D. Inhibition of HIV-1 infection by small interfering RNAmediated RNA interference. J Immunol. 2002;169(9):5196-201.
54. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, et al. siRNAdirected inhibition of HIV-1 infection. Nat Med. 2002;8(7):681-6.
55. ter Brake O, Konstantinova P, Ceylan M, Berkhout B. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther. 2006;14(6):883-92.
56. Gimenez-Barcons M, Clotet B, Martinez MA. Endoribonuclease-prepared short interfering RNAs induce effective and specific inhibition of human immunodeficiency virus type 1 replication. J Virol. 2007;81(19):10680-6.
57. Sabariegos R, Gimenez-Barcons M, Tapia N, Clotet B, Martinez MA. Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. J Virol. 2006;80(2):571-7.
58. Coburn GA, Cullen BR. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol. 2002;76(18):9225-31.
59. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol. 2002;20(5): 500-5.
60. Sano M, Li H, Nakanishi M, Rossi JJ. Expression of long anti-HIV-1 hairpin RNAs for the generation of multiple siRNAs: advantages and limitations. Mol Ther. 2008;16(1):170-7.
61. Lee SK, Dykxhoorn DM, Kumar P, Ranjbar S, Song E, Maliszewski LE, et al. Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood. 2005;106(3):818-26.
62. Konstantinova P, de Vries W, Haasnoot J, ter Brake O, de Haan P, Berkhout B. Inhibition of human immunodeficiency virus type 1 by RNA interference using long-hairpin RNA. Gene Ther. 2006;13(19):1403-13.
63. Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature. 2002;418(6896):435-8.
64. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995; 69(8):5087-94.
65. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B. Human immunodeficiency virus type 1 escape from RNA interference. J Virol. 2003;77(21):11531-5.
66. Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R, et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol. 2004;78(5):2601-5.
67. Westerhout EM, Ooms M, Vink M, Das AT, Berkhout B. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res. 2005; 33(2):796-804.
68. Saayman S, Arbuthnot P, Weinberg MS. Deriving four functional anti-HIV siRNAs from a single Pol III-generated transcript comprising two adjacent long hairpin RNA precursors. Nucleic Acids Res. 2010;38(19):6652-63.
69. Saayman S, Barichievy S, Capovilla A, Morris KV, Arbuthnot P, Weinberg MS. The efficacy of generating three independent anti-HIV-1 siRNAs from a single U6 RNA Pol III-expressed long hairpin RNA. PLoS One. 2008;3(7):e2602.
70. Saayman SM, Arbuthnot P, Weinberg MS. Effective Pol III-expressed long hairpin RNAs targeted to multiple unique sites of HIV-1. Methods Mol Biol. 2010;629:159-74.
71. Symonds GP, Johnstone HA, Millington ML, Boyd MP, Burke BP, Breton LR. The use of cell-delivered gene therapy for the treatment of HIV/AIDS. Immunol Res. 2010; 48(1-3):84-98.
72. Anderson J, Banerjea A, Akkina R. Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides. 2003;13(5):303-12.
73. Zhou J, Neff CP, Liu X, Zhang J, Li H, Smith DD, et al. Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther. 2011;19(12):2228-38. Epub 2011/09/29.
74. Anderson J, Akkina R. HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther. 2005;2(1):1.
75. Liang M, Kamata M, Chen KN, Pariente N, An DS, Chen IS. Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction. J Gene Med. 2010;12(3):255-65.
76. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral- mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A. 2003;100(1):183-8.
77. Zhou N, Fang J, Mukhtar M, Acheampong E, Pomerantz RJ. Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Gene Ther. 2004; 11(23):1703-12.
78. Surabhi RM, Gaynor RB. RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication. J Virol. 2002;76(24):12963-73.
79. Chiu YL, Cao H, Jacque JM, Stevenson M, Rana TM. Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1). J Virol. 2004;78(5):2517-29.
80. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ, et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science. 2008;319(5865):921-6.
81. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360(7):692-8.
82. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med. 2010;2(36):36ra43.
83. Li MJ, Bauer G, Michienzi A, Yee JK, Lee NS, Kim J, et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther. 2003;8(2):196-206. Epub 2003/08/09.
84. Zaia JA, Forman SJ. Transplantation in HIV-infected subjects: is cure possible? Hematol Am Soc Hematol Educ Program. 2013;2013:389-93.
85. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005;23(6):709-17.
86. Kumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell. 2008;134(4):577-86.
87. Peer D, Zhu P, Carman CV, Lieberman J, Shimaoka M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A. 2007;104(10):4095-100.
88. Kim SS, Peer D, Kumar P, Subramanya S, Wu H, Asthana D, et al. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther. 2010;18(2):370-6.
89. Eguchi A, Meade BR, Chang YC, Fredrickson CT, Willert K, Puri N, et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol. 2009;27(6):567-71.
90. Dassie JP, Giangrande PH. Current progress on aptamer-targeted oligonucleotide therapeutics. Ther Deliv. 2013;4(12):1527-46.
91. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990;346(6287):818-22.
92. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249(4968):505-10.
93. Stoltenburg R, Reinemann C, Strehlitz B. SELEX-a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng. 2007;24(4):381-403.
94. Shamah SM, Healy JM, Cload ST. Complex target SELEX. Acc Chem Res. 2008; 41(1):130-8.
95. Fitter S, James R. Deconvolution of a complex target using DNA aptamers. J Biol Chem. 2005;280(40):34193-201.
96. Blank M, Weinschenk T, Priemer M, Schluesener H. Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels selective targeting of endothelial regulatory protein pigpen. J Biol Chem. 2001;276(19):16464-8.
97. Cerchia L, Duconge F, Pestourie C, Boulay J, Aissouni Y, Gombert K, et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol. 2005;3(4):e123.
98. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci U S A. 2003;100(26):15416-21.
99. Guo KT, Ziemer G, Paul A, Wendel HP. CELL-SELEX: novel perspectives of aptamer-based therapeutics. Int J Mol Sci. 2008;9(4):668-78.
100. Morris KN, Jensen KB, Julin CM, Weil M, Gold L. High affinity ligands from in vitro selection: complex targets. Proc Natl Acad Sci U S A. 1998;95(6):2902-7.
101. Sefah K, Tang ZW, Shangguan DH, Chen H, Lopez-Colon D, Li Y, et al. Molecular recognition of acute myeloid leukemia using aptamers. Leukemia. 2009;23(2):235-44.
102. Shangguan D, Meng L, Cao ZC, Xiao Z, Fang X, Li Y, et al. Identification of liver cancerspecific aptamers using whole live cells. Anal Chem. 2008;80(3):721-8.
103. Thiel KW, Hernandez LI, Dassie JP, Thiel WH, Liu X, Stockdale KR, et al. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res. 2012;40(13):6319-37.
104. Thiel WH, Bair T, Peek AS, Liu X, Dassie J, Stockdale KR, et al. Rapid identification of cellspecific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection. PLoS One. 2012;7(9):e43836.
105. Hernandez LI, Flenker KS, Hernandez FJ, Klingelhutz AJ, McNamara 2nd JO, Giangrande PH. Methods for evaluating cell-specific, cell-internalizing RNA aptamers. Pharmaceuticals (Basel). 2013;6(3):295-319.
106. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010; 9(7):537-50.
107. Huang Y, Eckstein F, Padilla R, Sousa R. Mechanism of ribose 2′-group discrimination by an RNA polymerase. Biochemistry. 1997;36(27):8231-42.
108. Padilla R, Sousa R. Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2'-groups using a mutantT7 RNA polymerase (RNAP). Nucleic Acids Res. 1999; 27(6):1561-3.
109. Sousa R, Padilla R. A mutant T7 RNA polymerase as a DNA polymerase. EMBO J. 1995;14(18):4609-21.
110. Chelliserrykattil J, Ellington AD. Evolution of a T7 RNA polymerase variant that transcribes 2′-O-methyl RNA. Nat Biotechnol. 2004;22(9):1155-60.
111. Fa M, Radeghieri A, Henry AA, Romesberg FE. Expanding the substrate repertoire of a DNA polymerase by directed evolution. J Am Chem Soc. 2004;126(6):1748-54.
112. Ng EW, Adamis AP. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci. 2006;1082:151-71.
113. Keefe AD, Cload ST. SELEX with modified nucleotides. Curr Opin Chem Biol. 2008;12(4):448-56.
114. Sundaram P, Kurniawan H, Byrne ME, Wower J. Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci. 2013;48(1-2):259-71.
115. Held DM, Kissel JD, Patterson JT, Nickens DG, Burke DH. HIV-1 inactivation by nucleic acid aptamers. Front Biosci. 2006;11:89-112.
116. Shum KT, Zhou J, Rossi JJ. Aptamer-based therapeutics: new approaches to combat human viral diseases. Pharmaceuticals (Basel). 2013;6(12):1507-42.
117. Burke DH, Scates L, Andrews K, Gold L. Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase. J Mol Biol. 1996; 264(4):650-66.
118. Chaloin L, Lehmann MJ, Sczakiel G, Restle T. Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. Nucleic Acids Res. 2002; 30(18):4001-8.
119. Ditzler MA, Lange MJ, Bose D, Bottoms CA, Virkler KF, Sawyer AW, et al. High-throughput sequence analysis reveals structural diversity and improved potency among RNA inhibitors of HIV reverse transcriptase. Nucleic Acids Res. 2013;41(3):1873-84.
120. Held DM, Kissel JD, Saran D, Michalowski D, Burke DH. Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. J Biol Chem. 2006;281(35):25712-22.
121. Joshi P, Prasad VR. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J Virol. 2002;76(13):6545-57.
122. Kensch O, Connolly BA, Steinhoff HJ, McGregor A, Goody RS, Restle T. HIV-1 reverse transcriptase-pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity. J Biol Chem. 2000;275(24):18271-8.
123. Lange MJ, Sharma TK, Whatley AS, Landon LA, Tempesta MA, Johnson MC, et al. Robust suppression of HIV replication by intracellularly expressed reverse transcriptase aptamers is independent of ribozyme processing. Mol Ther. 2012;20(12):2304-14.
124. Li N, Wang Y, Pothukuchy A, Syrett A, Husain N, Gopalakrisha S, et al. Aptamers that recognize drug-resistant HIV-1 reverse transcriptase. Nucleic Acids Res. 2008;36(21): 6739-51.
125. Tuerk C, MacDougal S, Gold L. RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proc Natl Acad Sci U S A. 1992;89(15):6988-92.
126. Whatley AS, Ditzler MA, Lange MJ, Biondi E, Sawyer AW, Chang JL, et al. Potent Inhibition of HIV-1 Reverse Transcriptase and Replication by Nonpseudoknot, "UCAA-motif" RNA Aptamers. Mol Ther Nucleic Acids. 2013;2:e71.
127. Chou SH, Chin KH, Wang AH. DNA aptamers as potential anti-HIV agents. Trends Biochem Sci. 2005;30(5):231-4.
128. de Soultrait VR, Lozach PY, Altmeyer R, Tarrago-Litvak L, Litvak S, Andreola ML. DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents. J Mol Biol. 2002;324(2):195-203.
129. Phan AT, Kuryavyi V, Ma JB, Faure A, Andreola ML, Patel DJ. An interlocked dimeric parallel- stranded DNA quadruplex: a potent inhibitor of HIV-1 integrase. Proc Natl Acad Sci U S A. 2005;102(3):634-9.
130. Sgobba M, Olubiyi O, Ke S, Haider S. Molecular dynamics of HIV1-integrase in complex with 93del-a structural perspective on the mechanism of inhibition. J Biomol Struct Dyn. 2012;29(5):863-77.
131. Faure-Perraud A, Metifiot M, Reigadas S, Recordon-Pinson P, Parissi V, Ventura M, et al. The guanine-quadruplex aptamer 93del inhibits HIV-1 replication ex vivo by interfering with viral entry, reverse transcription and integration. Antivir Ther. 2011;16(3):383-94.
132. Jing N, Hogan ME. Structure-activity of tetrad-forming oligonucleotides as a potent anti-HIV therapeutic drug. J Biol Chem. 1998;273(52):34992-9.
133. Mazumder A, Neamati N, Ojwang JO, Sunder S, Rando RF, Pommier Y. Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry. 1996;35(43):13762-71.
134. Rando RF, Ojwang J, Elbaggari A, Reyes GR, Tinder R, McGrath MS, et al. Suppression of human immunodeficiency virus type 1 activity in vitro by oligonucleotides which form intramolecular tetrads. J Biol Chem. 1995;270(4):1754-60.
135. Magbanua E, Zivkovic T, Hansen B, Beschorner N, Meyer C, Lorenzen I, et al. d(GGGT) 4 and r(GGGU) 4 are both HIV-1 inhibitors and interleukin-6 receptor aptamers. RNA Biol. 2013;10(2):216-27.
136. Sayer N, Ibrahim J, Turner K, Tahiri-Alaoui A, James W. Structural characterization of a 2′FRNA aptamer that binds a HIV-1 SU glycoprotein, gp120. Biochem Biophys Res Commun. 2002;293(3):924-31.
137. Khati M, Schuman M, Ibrahim J, Sattentau Q, Gordon S, James W. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-RNA aptamers. J Virol. 2003;77(23):12692-8.
138. Cohen C, Forzan M, Sproat B, Pantophlet R, McGowan I, Burton D, et al. An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site. Virology. 2008;381(1):46-54.
139. Dey AK, Griffiths C, Lea SM, James W. Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. RNA. 2005;11(6):873-84.
140. Dey AK, Khati M, Tang M, Wyatt R, Lea SM, James W. An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J Virol. 2005;79(21):13806-10.
141. Joubert MK, Kinsley N, Capovilla A, Sewell BT, Jaffer MA, Khati M. A modeled structure of an aptamer-gp120 complex provides insight into the mechanism of HIV-1 neutralization. Biochemistry. 2010;49(28):5880-90.
142. Mufhandu HT, Gray ES, Madiga MC, Tumba N, Alexandre KB, Khoza T, et al. UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C. J Virol. 2012;86(9):4989-99.
143. Zhou J, Swiderski P, Li H, Zhang J, Neff CP, Akkina R, et al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 2009;37(9):3094-109.
144. Zhou J, Li H, Li S, Zaia J, Rossi JJ. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther. 2008;16(8):1481-9.
145. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol. 2005;23(2):222-6.
146. Neff CP, Zhou J, Remling L, Kuruvilla J, Zhang J, Li H, et al. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med. 2011;3(66):66ra6.
147. Zhou J, Neff CP, Swiderski P, Li H, Smith DD, Aboellail T, et al. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther. 2013;21(1):192-200.
148. Zhou J, Shu Y, Guo P, Smith DD, Rossi JJ. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods. 2011;54(2):284-94.
149. Wheeler LA, Trifonova R, Vrbanac V, Basar E, McKernan S, Xu Z, et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamersiRNA chimeras. J Clin Invest. 2011;121(6):2401-12.
150. Wheeler LA, Vrbanac V, Trifonova R, Brehm MA, Gilboa-Geffen A, Tanno S, et al. Durable knockdown and protection from HIV transmission in humanized mice treated with gelformulated CD4 aptamer-siRNA chimeras. Mol Ther. 2013;21(7):1378-89.
151. Zhu Q, Shibata T, Kabashima T, Kai M. Inhibition of HIV-1 protease expression in T cells owing to DNA aptamer-mediated specific delivery of siRNA. Eur J Med Chem. 2012;56:396-9.
152. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, Sodroski J, et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure. 2000;8(12):1329-39.
153. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 1998;393(6686): 705-11.
154. Rockey WM, Hernandez FJ, Huang SY, Cao S, Howell CA, Thomas GS, et al. Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acids Ther. 2011;21(5):299-314.